The price of Atreca Inc. (NASDAQ:BCEL) shares last traded on Wall Street fell -1.86% to $1.58.
Based on available information, 9 analysts follow Atreca Inc. (NASDAQ:BCEL). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $25.00 and a low of $2.00, we find $10.00. Given the previous closing price of $1.61, this indicates a potential upside of 521.12 percent. BCEL stock price is now 37.22% away from the 50-day moving average and -9.20% away from the 200-day moving average. The market capitalization of the company currently stands at $58.89M.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
Among analysts, 0 rate the stock a hold while 9 rate it a buy. Brokers who have rated the stock have averaged $12.00 as their price target over the next twelve months.
On February 08, 2021, Jefferies recently initiated its ‘Buy’ rating on the stock quoting a target price of $30, while ‘Wedbush’ rates the stock as ‘Outperform’.
In other news, Serafini Tito, Chief Strategy Officer sold 7,646 shares of the company’s stock on Sep 02. The stock was sold for $13,573 at an average price of $1.78. Upon completion of the transaction, the Chief Strategy Officer now directly owns 34,554 shares in the company, valued at $54595.32. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 02, President & CEO Orwin John A sold 20,908 shares of the business’s stock. A total of $37,116 was realized by selling the stock at an average price of $1.78. This leaves the insider owning 100,492 shares of the company worth $0.16 million. Insiders disposed of 87,632 shares of company stock worth roughly $0.14 million over the past 1 year. A total of 0.60% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in BCEL stock. A new stake in Atreca Inc. shares was purchased by GSA CAPITAL PARTNERS LLP during the first quarter worth $302,000. AMALGAMATED FINANCIAL CORP. invested $5,000 in shares of BCEL during the first quarter. In the first quarter, GLOBAL TRUST ASSET MANAGEMENT, LLC acquired a new stake in Atreca Inc. valued at approximately $2,000. In total, there are 110 active investors with 50.20% ownership of the company’s stock.
A candlestick chart of Atreca Inc. (NASDAQ: BCEL) showed a price of $1.6200 on Thursday morning. During the past 12 months, Atreca Inc. has had a low of $0.76 and a high of $5.36. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 6.40, and a quick ratio of 6.40. The fifty day moving average price for BCEL is $1.1515 and a two-hundred day moving average price translates $1.7401 for the stock.
The latest earnings results from Atreca Inc. (NASDAQ: BCEL) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.72, missing analysts’ expectations of -$0.71 by -0.01. This compares to -$0.74 EPS in the same period last year. The company reported revenue of $23.29 million for the quarter, compared to $27.52 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -15.35 percent.
Atreca Inc.(BCEL) Company Profile
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company’s ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients. It also developing APN-122597, a receptor tyrosine kinase that target tumor tissues; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. Atreca, Inc. was incorporated in 2010 and is based in San Carlos, California.
